Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
US9714278B2 · kind B2 · utility
30Cited by
34References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2013 |
| Grant date | Jul 25, 2017 |
| Priority date | — |
| Expiry date | Mar 10, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.